Spero Therapeutics Inc. is a multi-asset, clinical-stage biopharmaceutical company. It focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections. Spero Therapeutics Inc. is based in CAMBRIDGE, United States.
| Revenue (Most Recent Fiscal Year) | $47.98M |
| Net Income (Most Recent Fiscal Year) | $-68.57M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.67 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.52 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -156.48% |
| Net Margin (Trailing 12 Months) | -156.48% |
| Return on Equity (Trailing 12 Months) | -123.50% |
| Return on Assets (Trailing 12 Months) | -58.96% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.56 |
| Quick Ratio (Most Recent Fiscal Quarter) | 2.56 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.60 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.25 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.27 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.28 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 55.91M |
| Free Float | 53.38M |
| Market Capitalization | $119.09M |
| Average Volume (Last 20 Days) | 9.63M |
| Beta (Past 60 Months) | 0.23 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 4.52% |
| Percentage Held By Institutions (Latest 13F Reports) | 25.60% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |